Next-Generation Bilayer Tablets for Personalized Medicine and Enhanced Efficacy

A novel, multi-layered tablet design that integrates sequential release of active pharmaceutical ingredients, pH-dependent coatings, and companion diagnostic devices for personalized medicine, offering improved efficacy and patient outcomes.

The original patent disclosed bilayer tablets comprising acetylsalicylic acid and pseudoephedrine. However, these tablets have limitations in terms of release profiles, dissolution rates, and patient-specific dosing. The new inventive concept addresses these limitations by introducing a multi-layered design, advanced manufacturing techniques, and integrated diagnostic devices.

The next-generation bilayer tablets comprise three layers: a first layer containing acetylsalicylic acid and pseudoephedrine, a second layer containing a dissolution aid, and a third layer featuring a pH-dependent coating. This design enables sequential release of the active pharmaceutical ingredients, providing rapid relief from symptoms and sustained therapeutic effects. The tablets are manufactured using a novel combination of 3D printing and hot-melt extrusion techniques, allowing for complex geometries and customized release profiles. Furthermore, the tablets are paired with a companion diagnostic device that provides real-time feedback on an individual's response to the active pharmaceutical ingredients, enabling personalized dosing and treatment regimens.

The new claims introduce a paradigm shift in bilayer tablet design, manufacturing, and functionality. The multi-layered design, advanced manufacturing techniques, and integrated diagnostic devices provide a novel and non-obvious solution that significantly improves upon the original patent.

Alternative embodiments of the inventive concept could include tablets with varying layer compositions, geometries, and release profiles tailored to specific patient populations or disease indications. Additionally, the diagnostic device could be integrated with artificial intelligence and machine learning algorithms to optimize treatment outcomes and predict patient responses.

The next-generation bilayer tablets have significant commercial potential in the pharmaceutical industry, particularly in the areas of personalized medicine, respiratory health, and pain management. The integrated diagnostic device and advanced manufacturing techniques offer a competitive advantage in the market, with potential applications in hospital settings, clinical trials, and direct-to-consumer sales.